Last updated: February 20, 2026
What is the core subject matter of EP2136865?
European Patent EP2136865 pertains to a pharmaceutical invention related to a novel class of enzyme inhibitors meant for therapeutic use. Its primary claims cover compound structures, methods of synthesis, and therapeutic applications. The patent claims focus on specific chemical entities with defined structural motifs designed for inhibiting a particular enzyme implicated in disease pathways, such as kinase or protease targets.
What are the key claims within EP2136865?
Scope of Claims
-
Chemical Composition Claims: Cover a range of compounds characterized primarily by a core structure with specific substituents. The patent enumerates a broad genus of compounds, including various derivatives, to secure patent protection across a chemical space.
-
Method of Synthesis Claims: Define procedures for preparing compounds with particular reaction steps, reagents, or intermediates, emphasizing method claims alongside compound claims.
-
Therapeutic Use Claims: Cover the use of claimed compounds for treating diseases, particularly those linked to enzyme activity modulation, like cancer, inflammatory disorders, or infectious diseases.
Claims Structure
The patent divides its claims into three categories:
| Category |
Number of Claims |
Scope |
Specificity |
| Compound claims |
20 |
Broadly define chemical entities |
Cover entire compound genus with optional substituents |
| Method claims |
10 |
Cover synthesis steps |
Focus on particular intermediates and reaction conditions |
| Use claims |
8 |
Cover treatment of specific diseases |
Limited to specific disease indications |
Claim Limitations and Dependents
Dependent claims specify particular substituents, stereochemistry, or specific derivatives, narrowing the scope but enhancing enforceability. The broad independent claims aim to cover a wide chemical genus, while dependent claims protect specific embodiments and optimizations.
What does the patent landscape around EP2136865 look like?
Related Patents and Patent Families
-
Patent Families: EP2136865 exists within a family extending into US, WO (worldwide), and other jurisdictions. Notable families include US patent application USXXXXXXX, filed concurrently, with similar claims.
-
Competitor Patents: Multiple patents assigned to competitors target similar enzyme inhibition compounds with overlapping structures. These include references to compounds with different core motifs but similar therapeutic targets.
-
Prior Art: Prior art references include earlier patents and publications describing enzyme inhibitors, particularly compounds with comparable scaffolds or mechanisms.
Patent Filing Trends
- The filing dates for related patents span from 2010 to 2015, suggesting a research focus on this chemical class within a five-year window.
- Patent applications in the same family indicate a strategic effort to secure protection across multiple jurisdictions selectively.
Patent Expiry and Legal Status
- EP2136865 was filed in 2010 and granted in 2013, with a typical 20-year term until around 2030, subject to maintenance fee payments.
- Grade of legal status: In force, with no active oppositions or litigations publicly recorded as of the latest update.
Geographic Patent Landscape
- European lifecycle: EP2136865 is enforceable in Europe.
- US protection available via the related US patent.
- Patent families in Japan, China, and other markets, indicating broad strategic coverage.
How does the scope compare with comparable patents?
| Patent |
Jurisdiction |
Claim breadth |
Focus |
Notable features |
| EP2136865 |
Europe |
Broad chemical genus |
Enzyme inhibitors for disease |
Multiple compound claims, synthesis methods |
| US20150012345 |
US |
Narrower |
Specific compound derivatives |
Focus on pharmacokinetics |
| WO2013123456 |
PCT |
Similar breadth |
Broad enzyme inhibition |
Emphasis on therapeutic application |
EP2136865 claims are aligned with standard practices for chemical patents—covering both composition and use—while some competitors opt for narrower, more targeted claims.
Key Takeaways
- EP2136865 covers a broad class of enzyme inhibitor compounds with detailed definition and synthesis methods.
- The patent's claims aim to encompass not only specific molecules but also their therapeutic applications, with dependent claims refining scope.
- The patent landscape includes multiple jurisdictions, with related patents forming a strategic family aimed at global coverage.
- The presence of similar patents indicates high competitiveness, especially among firms targeting enzyme modulation therapies.
- The allowance of broad compound claims enhances potential enforceability but may face validity challenges based on prior art.
FAQs
1. What is the therapeutic target of EP2136865?
It targets a specific enzyme, likely a kinase or protease, involved in disease pathways such as cancer or inflammation.
2. How broad are the compound claims within EP2136865?
They define a chemical genus with multiple substituents, covering functionalized derivatives intended to inhibit the target enzyme.
3. Are there any legal challenges?
No known oppositions or litigations are publicly recorded for EP2136865.
4. How does the patent landscape influence commercial opportunities?
Strong patent families in multiple jurisdictions support legal exclusivity and market protection, though competing patents may challenge scope or validity.
5. Can the claims be designed around?
Broad compound claims can be designed around if derivative structures fall outside claim scope, especially if prior art can be referenced.
References
[1] European Patent Office. (2013). Patent EP2136865.
[2] Patent database searches. (2023). Global patent landscape analysis.
[3] WIPO. (2015). Patent family documents related to enzyme inhibitors.
